|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0019682,
umls-concept:C0019704,
umls-concept:C0024398,
umls-concept:C0042210,
umls-concept:C0042216,
umls-concept:C0205250,
umls-concept:C0205349,
umls-concept:C0442335,
umls-concept:C0442711,
umls-concept:C0805586,
umls-concept:C1623048,
umls-concept:C1704419,
umls-concept:C2587213
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2004-3-29
|
|
pubmed:abstractText |
Previous studies have shown that vaccination and boosting of rhesus macaques with attenuated vesicular stomatitis virus (VSV) vectors encoding Env and Gag proteins of simian immunodeficiency virus-human immunodeficiency virus (SHIV) hybrid viruses protect rhesus macaques from AIDS after challenge with the highly pathogenic SHIV 89.6P (23). In the present study, we compared the effectiveness of a single prime-boost protocol consisting of VSV vectors expressing SHIV Env, Gag, and Pol proteins to that of a protocol consisting of a VSV vector prime followed with a single boost with modified vaccinia virus Ankara (MVA) expressing the same SHIV proteins. After challenge with SHIV 89.6P, MVA-boosted animals controlled peak challenge viral loads to less than 2 x 10(6) copies/ml (a level significantly lower than that seen with VSV-boosted animals and lower than those reported for other vaccine studies employing the same challenge). MVA-boosted animals have shown excellent preservation of CD4(+) T cells, while two of four VSV-boosted animals have shown significant loss of CD4(+) T cells. The improved protection in MVA-boosted animals correlates with trends toward stronger prechallenge CD8(+)-T-cell responses to SHIV antigens and stronger postchallenge SHIV-neutralizing antibody production.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-10519927,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-10559336,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-11039923,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-11069984,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-11101083,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-11145906,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-11153085,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-11333896,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-11393868,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-11551502,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-11797011,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-11797012,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-11861598,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-12001995,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-12009868,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-12097563,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-12438610,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-1438287,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-2078405,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-2182912,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-7753828,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-8551612,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-8642658,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-8794335,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-9151808,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-9188571,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-9525675,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15047809-9603331
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0022-538X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
78
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3930-40
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:15047809-AIDS Vaccines,
pubmed-meshheading:15047809-Acquired Immunodeficiency Syndrome,
pubmed-meshheading:15047809-Animals,
pubmed-meshheading:15047809-Base Sequence,
pubmed-meshheading:15047809-CD4 Lymphocyte Count,
pubmed-meshheading:15047809-CD8-Positive T-Lymphocytes,
pubmed-meshheading:15047809-DNA, Recombinant,
pubmed-meshheading:15047809-Genetic Vectors,
pubmed-meshheading:15047809-HIV,
pubmed-meshheading:15047809-HIV Antibodies,
pubmed-meshheading:15047809-Immunization, Secondary,
pubmed-meshheading:15047809-Macaca mulatta,
pubmed-meshheading:15047809-SAIDS Vaccines,
pubmed-meshheading:15047809-Simian Acquired Immunodeficiency Syndrome,
pubmed-meshheading:15047809-Simian immunodeficiency virus,
pubmed-meshheading:15047809-Vaccines, Synthetic,
pubmed-meshheading:15047809-Vaccinia virus,
pubmed-meshheading:15047809-Vesicular stomatitis Indiana virus
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol.
|
|
pubmed:affiliation |
Yale University School of Medicine, New Haven, Connecticut 06510, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
